About half of people with metastatic lung cancer are offered nothing. No chemotherapy. No immunotherapy. No targeted pills that can shrink tumors for months while patients keep working and parenting and planning. A new analysis of clinical and claims data shows that even as checkpoint inhibitors and EGFR inhibitors transform oncology guidelines, they still bypass a stunning share of those who need them most.
The harsh truth is that biology is no longer the only barrier; the care system is. Researchers report that many patients reach an oncologist only when their performance status has already collapsed, making cytotoxic chemotherapy unsafe despite theoretical benefit. Others disappear in the gap between a positive CT scan and a completed biomarker panel, never getting the molecular profiling that would flag an ALK or EGFR mutation and route them to precision therapy.
Cost and bias do the rest. Clinicians, pressed for time, often assume older or poorer patients will not tolerate or afford PD‑1 blockade or oral tyrosine kinase inhibitors, even when toxicity profiles and survival curves argue otherwise. Insurers demand prior authorizations, turning each prescription into a bureaucratic skirmish that some hospitals are better staffed to win. So the most lethal solid tumor becomes a quiet triage exercise, where science has sprinted ahead and access still limps behind.
